🇺🇸 FDA

Company profile · Sponsor

Outlook

Outlook Therapeutics NL B. V.

OTLK · NYSE pharma ISELIN, NJ, EU
Pipeline
2
Drugs
1
Patents
2

Quick answer

Outlook (OTLK) is a pharma company. headquartered in ISELIN, NJ, EU. listed on NYSE. NovaPharmaNews links 2 pipeline programs, 1 drug, and 2 patents to this profile..

Company facts

Ticker OTLK
Exchange NYSE
Company type pharma
Headquarters ISELIN, NJ, EU
SEC CIK 0001649989

Pipeline (2)

Search pipeline →

  1. bevacizumab

    Outlook

    Age-related Macular Degeneration

    phase 3 mab active

    4 trials

  2. bevacizumab

    Outlook

    Neovascular Age-related Macular Degeneration

    phase 3 mab completed

    1 trial

Drugs (1)

Search drugs →

  1. bevacizumab

    KYOMARC

    INTRAVENOUS approved

    L01FG01

Patents (2)

Search patents →

  1. US 11285210

    Buffer formulations for enhanced antibody stability

    Expires Mon Mar 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10376582

    Buffer formulations for enhanced antibody stability

    Expires Mon Aug 08 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is Outlook?

Outlook (OTLK) is a pharma company. headquartered in ISELIN, NJ, EU. listed on NYSE. NovaPharmaNews links 2 pipeline programs, 1 drug, and 2 patents to this profile..

What pipeline programs does Outlook sponsor?

We track 2 ClinicalTrials.gov-linked programs for Outlook, including bevacizumab and 1 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Outlook company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.